Zydus Lifesciences Limited has informed the Exchange regarding a press release dated April 25, 2025, titled "Zydus Lifesciences Limited signs purchase agreement with PAI Partners and other shareholders to acquire a majority stake in Amplitude Surgical SA".
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zydus Lifesciences has signed a share purchase agreement to acquire 85.6% of French orthopaedic surgical technologies company Amplitude Surgical SA at €6.25 per share. The stake is being bought from private equity firm PAI Partners, Amplitude CEO Olivier Jallabert, and other managers, plus two minority shareholders. Amplitude is a leading French player in lower-limb orthopaedic products (hip and knee), with annual sales of around €106 million and 428 employees as of mid-2024. The deal is subject to French regulatory approvals and is expected to close by Q3 2025, after which Zydus will file a mandatory tender offer with French markets regulator AMF, likely followed by a squeeze-out of remaining shareholders.
This is a significant cross-border acquisition that expands Zydus into the global orthopaedic medical devices market and diversifies its revenue base beyond its core India pharma business. Shareholders should view this positively as a growth-oriented move, though near-term stock impact may be muted until deal closure and financial details emerge.